CHICAGO, IL -- February 26, 2007 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today debuted at PITTCON® 2007, Booth 843, an advanced spectroscopy tool combining optimized near-infrared (NIR) and optimized mid-infrared (MIR) spectroscopy in a single, research-grade instrument.  The Spectrum™ 400 features the ability to automatically switch between NIR and MIR measurement modes and dual sampling positions, enabling the user to rapidly change between applications to drive productivity with automatic, push-button ease.  It will aid in research, method development, analysis and trouble-shooting in a broad range of chemical and material, pharmaceutical and academic applications.

“The Spectrum 400 was developed in response to  customer demand for more flexible, high-performance NIR and MIR testing to enable thorough product and process research,” said Simon Wells, Ph.D., Molecular Spectroscopy business unit manager, PerkinElmer Life and Analytical Sciences.  “The spectrometer offers a high level of sampling and applications versatility to provide more analytical information.  It incorporates a unique design that is extremely robust, fast and simple to operate.”

The Spectrum 400 is offered with an extensive software suite, including PerkinElmer’s AssureIDTM software, which guides and trouble-shoots method development and validation and also provides a simple interface for manufacturing analysis.  This results in much faster method development, more robust testing procedures and a high level of confidence in results.

Available for shipment in May, the Spectrum 400 further supports increased product understanding with the ability to be used in conjunction with the recently introduced PerkinElmer Spotlight™ 400 FT-IR Imaging System, enabling MIR, NIR and attenuated total reflectance (ATR) imaging capabilities.  For the first time, customers can measure the large area distribution of components in materials with up to 3µ spatial resolution on the same platform used to measure bulk samples.

The Spectrum 400 instrumentation also includes a number of exclusive and patented FT-IR design approaches to increase the quality of data obtained and ensure consistency of measurements over time and between instruments.  These features, which include high-quality optical components and a broad range of sampling options, are carried through the Spectrum 100, 100N and 400 range to ensure that methods and spectra can be easily transferred between research and routine-testing laboratories.  “This instrument’s scalability enables smooth analytical roll-out as companies expand globally,” Wells noted.

For more information about the Spectrum 400, visit www.perkinelmer.com/spectrum400.

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements.  Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct.  A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. 

These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging.  Photonics markets include sensors and specialty lighting.